Amendment 250 to article 16, after paragraph 2
Framework for strengthening the availability and security of supply of critical medicinal products as well as the availability of, and accessibility of, medicinal products of common interest
A10-0272/2025 – Tomislav Sokol – Article 16, after § 2 – Am 250
Rejected
- For
- 141
- Against
- 516
- Abstained
- 7
roll-call vote at 12:47 · 21% of votes cast in favour
Roll call requested by The Left
How the groups voted
A group’s line is the position at least two thirds of its voting MEPs took; otherwise it is shown as Divided. Groups from left to right.
| Group | For | Against | Abstained | of | Line |
|---|---|---|---|---|---|
| The Left | 39 | 0 | 0 | 39 | For |
| Greens | 51 | 0 | 0 | 51 | For |
| S&D | 32 | 91 | 2 | 125 | Against |
| Renew | 1 | 66 | 1 | 68 | Against |
| EPP | 1 | 181 | 0 | 182 | Against |
| ECR | 0 | 70 | 1 | 71 | Against |
| Patriots | 0 | 78 | 0 | 78 | Against |
| ESN | 0 | 23 | 1 | 24 | Against |
| No group | 17 | 7 | 2 | 26 | — |
“of” = MEPs of the group who voted. Groups as they are now.
Every MEP
26 MEPs of 664 Clear filters
“Votes in which an MEP voted differently from their group: on decision pages, against a line at least two thirds of the group took; in loyalty figures, against the position most of the group took.” = voted otherwise than a clear line (two thirds of its votes) of the group they sit in now. MEPs with no vote recorded are not listed.